Clinical trials: Coronary Stent Occlusion
Angina, Coronary Occlusion
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
The objectives of the PMS are to observe the frequency, type, and degree of device deficiency to assure the safety of the new medical device (XIENCE PRIME) as well as to collect information on evaluation of the efficacy and…
- Conditions
- Angina, Coronary Occlusion, Coronary Artery Disease, Coronary Artery Stenosis
- Trial name
- NCT01721096
- Testing
- XIENCE PRIME - Long Length (LL), XIENCE PRIME - Core Size
- Where
- Japan
- Volunteers
- 536 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease (CAD), Chronic Total Occlusion of Coronary Artery
Predictors and Long-term Incidence of In-stent Restenosis After Chronic Total Occlusion Percutaneous Coronary Intervention
The goal of this clinical trial is to describe the long-term (≥ 3 years) patency of coronary artery stents following chronic total occlusion percutaneous coronary intervention (CTO PCI).
- Conditions
- Coronary Artery Disease (CAD), Chronic Total Occlusion of Coronary Artery, Chronic Total Occlusion (CTO)
- Trial name
- NCT07473596
- Testing
- chronic total occlusion percutaneous coronary intervention (CTO PCI), coronary computed tomography angiography, invasive coronary angiography
- Where
- Finland
- Volunteers
- 294 people
- Sponsor
- Lauri Mansikkaniemi
Coronary Artery Disease
Deutsches Dual Therapy Stent Register
The DTS.DE registry is an initiative for the collection of high quality process and historical data of implantations with the COMBO Dual Therapy Stent in Germany.
- Trial name
- DTS Register (NCT02102997)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- OrbusNeich
Coronary Artery Disease
Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions?
How to use drug eluting stents (DES) in bifurcation lesions. A strategy of routine stenting of both main vessel and side branch versus a strategy of routine main vessel stenting and optional treatment of side branch.
- Trial name
- BIFI (NCT00376571)
- Testing
- Percutaneous coronary intervention
- Where
- Denmark
- Volunteers
- 413 people
- Sponsor
- Aarhus University Hospital Skejby
Coronary Arteriosclerosis
Multicenter Postmarket Surveillance Registry Evaluating Performance and Long Term Safety of the Presillion Stent
The purpose of this study is: To evaluate the safety and performance of the Presillion stent in routine clinical practice.
- Trial name
- NCT00968019
- Testing
- Presillion stent
- Where
- 13 sites in Portugal, Spain
- Volunteers
- 318 people
- Sponsor
- Johnson and Johnson, S.A.
Coronary Artery Disease
Registry to Evaluate Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting
The objective of this study is to evaluate the safety and long-term effectiveness of coronary stenting with the everolimus-eluting stent (EES) and to determine clinical device and procedural success during commercial use of EES…
- Trial name
- NCT00960648
- Testing
- Xience/Promus, Cypher
- Where
- 18 sites in South Korea
- Volunteers
- 3,056 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations
The purpose of this study is to evaluate if the use of a phone based motivational interviewing among minority populations who received a coronary stent can improve adherence to antiplatelet agents from approximately 51% to 66%…
- Trial name
- NCT01651208
- Testing
- Motivational Interviewing (MINT), Mailed DVD
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- University of Miami
Coronary Artery Disease, Ischemic Heart Disease
Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent
The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is to compare the safety and efficacy of the sirolimus eluting ORSIRO stent and the biolimus-eluting NOBORI stent in a population-based…
- Trial name
- SORT OUT VII (NCT01879358)
- Testing
- Drug-eluting stent
- Where
- Denmark
- Volunteers
- 2,314 people
- Sponsor
- Odense University Hospital
Coronary Artery Disease
1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials
Prospective, multicenter, randomized, double-blind, placebo-controlled trials.
- Trial name
- NCT03971500
- Testing
- AntiPlatelet therapy, Percutaneous coronary intervention
- Where
- China
- Volunteers
- 3,710 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Angioplasty, Chronic Coronary Occlusion
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort…
- Conditions
- Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease
- Trial name
- XV CHINA SAS (NCT01249027)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
- Where
- United States
- Volunteers
- 2,605 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
PROMUS Element Plus US Post-Approval Study
This study is designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice.
- Trial name
- NCT01589978
- Testing
- PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
- Where
- 52 sites in United States
- Volunteers
- 2,681 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Effects of DES Platforms on Markers of Endothelial Damage and Inflammation
Percutaneous coronary intervention (PCI) with stenting may induce endothelial damage/dysfunction and inflammatory reactions, which in turn delay healing and endothelialization and may lead to restenosis and atherosclerosis within…
- Trial name
- PLATFORM (NCT01489202)
- Testing
- platinum chromium everolimus-eluting stent, cobalt chromium everolimus-eluting stent
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Angina, Chronic Coronary Occlusion
XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan
The objectives of this post-marketing surveillance, conducted in Japan, is to know the frequency, type and degree of device malfunction, to assure the safety of the medical device, and to collect information on evaluation of the…
- Conditions
- Angina, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease
- Trial name
- NCT01086228
- Testing
- XIENCE V / PROMUS stent
- Where
- 47 sites in Japan
- Volunteers
- 2,010 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Intravascular Optical Coherence Tomography Imaging - Length of Anti-Platelet Therapy After Drug Eluting Stent Placement
Patients who receive drug-coated stents (as opposed to the less frequently used bare metal stents) are currently recommended aspirin plus a thienopyridine such as Plavix, Effient, or Ticlid for one year.
- Trial name
- FDI-DAPT-ZES (NCT01219894)
- Sponsor
- Emory University
Coronary Artery Disease
Nordic Bifurcation Stent Technique Study (BIF II)
This is a study of crush- or culotte stenting of bifurcation lesions using drug eluting stents. This is a randomized Nordic multicenter study including 400 patients with angina pectoris with clinical angiographic follow-up.
- Trial name
- BIF II (NCT00292305)
- Testing
- Percutaneous coronary intervention
- Where
- Denmark
- Volunteers
- 425 people
- Sponsor
- Aarhus University Hospital Skejby
Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Trial name
- XVU-Phase 1 (NCT00676520)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- United States
- Volunteers
- 8,053 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Drug-Coated Balloon Versus Drug-eluting Stent Angioplasty for Treatment of Chronic Total Occlusion - The DCB-CTO Trial
Chronic total occlusion (CTO) remains one of the most challenging lesions in coronary artery disease management. Percutaneous coronary intervention using drug-eluting stents is currently a standard treatment approach; however…
- Trial name
- DCB-CTO (NCT07369765)
- Testing
- Drug-Eluting Stent Group, Drug Coated Balloon Group
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Biruni University
Hypertension, Coronary Artery Disease
Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was…
- Trial name
- NCT00139386
- Testing
- Candesartan
- Where
- Japan
- Volunteers
- 1,119 people
- Sponsor
- Kumamoto University
Coronary Artery Disease
Sirolimus-Eluting Stent Versus Standard Stent in Diabetic
The purpose of this study was to determine whether Sirolimus stent implantation is effective in reducing neointimal hyperplasia as compared to Bare metal stent in diabetic patients with de novo coronary artery stenosis.
- Trial name
- DIABETES (NCT00755443)
- Testing
- Drug eluting stent, Bare metal stent
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- Hospital San Carlos, Madrid
Restenosis, Coronary, Left Main Coronary Artery Disease
PCI vs. CABG in UPLM-ISR
Left main (LM) coronary artery disease is associated with high morbidity and mortality owing to the large myocardial territory at risk for ischemia.
- Conditions
- Restenosis, Coronary, Left Main Coronary Artery Disease, PTCA Left Main Artery Complications
- Trial name
- LM-DRAGON (NCT04968977)
- Testing
- PCI vs. CABG
- Where
- 11 sites in Italy, Poland
- Volunteers
- 305 people
- Sponsor
- Medical University of Silesia